Brought to you by 
Amgen buys Abgenix
Dec 2005
Executive Summary
Amgen will pay about $2.2bn in cash to acquire its three-year partner, therapeutic antibody company Abgenix Inc. Abgenix stockholders get $22.50 per common share, about a 57% premium to market. Amgen will also acquire Abgenix's $703mm of outstanding debt.
Deal Industry
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Intra-Biotech Deal
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amgen buys Abgenix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice